-
-
-
-
-
-
-
Pfizer Declares Fourth-Quarter 2026 Dividend
-
-
-
-
-
-
-
Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
-
-
-
-
-
-
-
Pfizer (PFE) Tops Q2 EPS by 9c, Beats on Revenue; Offers FY26 EPS Guidance
-
-
-
-
-
-
-
FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
-
-
-
-
-
-
-
Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
-
-
-
-
-
-
-
Pfizer Announces Chief Financial Officer Transition
-
-
-
-
-
-
-
Pfizer drug combination cuts prostate cancer progression risk by 52%
-
1,232,655 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


